Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
09. Januar 2023 08:30 ET
|
Neuronetics
MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
29. Dezember 2022 16:29 ET
|
Neuronetics
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07. Dezember 2022 16:30 ET
|
Neuronetics
MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
05. Dezember 2022 08:32 ET
|
Neuronetics
MALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
21. November 2022 16:30 ET
|
Neuronetics
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
14. November 2022 08:33 ET
|
Neuronetics
MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09. November 2022 20:04 ET
|
Neuronetics
MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Third Quarter 2022 Financial and Operating Results
08. November 2022 07:30 ET
|
Neuronetics
MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
31. Oktober 2022 08:31 ET
|
Neuronetics
MALVERN, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
25. Oktober 2022 10:31 ET
|
Neuronetics
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...